Novartis AG (NVSEF)
| Market Cap | 194.81B |
| Revenue (ttm) | 49.94B |
| Net Income (ttm) | 17.60B |
| Shares Out | n/a |
| EPS (ttm) | 8.58 |
| PE Ratio | 11.07 |
| Forward PE | n/a |
| Dividend | 5.23 (4.75%) |
| Ex-Dividend Date | Oct 4, 2023 |
| Volume | 5,300 |
| Open | 95.49 |
| Previous Close | 94.70 |
| Day's Range | 95.49 - 95.49 |
| 52-Week Range | 90.24 - 123.55 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 31, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and ... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial StatementsNews
Novartis to close MorphoSys sites in Boston, Munich: report
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports
Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying...
BioAge, Novartis team up to discover age-related disease targets
Novartis participates in Healthway Cancer Care Hospital ‘Celebrating Strength’ event championing breast cancer survivorship
In celebration of Breast Cancer Awareness Month, HealthwayCancer Care Hospital hosted the “Celebrating Strength: A Day for Breast Cancer Patients” last October 28, 2024.
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™
Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA-positive metastatic castration-resistant prostate cancer MONTREAL , Dec. 13, 2024 /CNW/ - Novartis ...
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc...
Novartis: Time To Increase
Novartis' key growth drivers include higher investments in R&D and strategic early stake acquisitions. Find out why NVS stock is a Buy.
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Basel, December 10, 2024 – Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the du...
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix® (asciminib) showing superior major molecular response (MMR) r...
12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style
The S&P is up almost 28% in 2024, and many investors worry about a melt-up followed by a sharp correction like in 2022 or 2018. A 2025 market correction is likely, but low-volatility, high-yield Divid...
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
On Friday, Novartis AG (NYSE: NVS) revealed topline results from the APPULSE-PNH Phase 3B study of Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switc...
Novartis reports positive Phase 3b data for Fabhalta in PNH
Novartis (NVS) reported positive Phase 3b data from a study of its drug Fabhalta for the treatment of paroxysmal nocturnal hemoglobinuria, or PNH. Read more here.
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
Basel, December 6, 2024 – Novartis today announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan...
Aurobindo Pharma arm Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg
Aurobindo Pharma Limited announced that its wholly-owned subsidiary, Eugia Pharma Specialities Limited, has secured final approval from the US Food and Drug Administration (USFDA) to manufacture and m...
Monte Rosa Therapeutics: A First Assessment
Monte Rosa Therapeutics stock surged after a recent partnership with Novartis, despite limited clinical results. Can the rally continue? Read our full assessment on Seeking Alpha.
Novartis loses appeal to block generic Entresto launch: report
Novartis cannot block generic of best-selling heart drug, US appeals court says
Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' blockbuster heart drug Entresto.
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
On Monday, Janux Therapeutics, Inc. (NASDAQ: JANX) revealed updated interim clinical data for its JANX007 clinical program . “These clinical data show substantial activity with JANX007 in 5L metastat...
PTC upgraded to outperform by RBC on Novartis deal
Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. (NASDAQ: PTCT) signed an exclusive global license and collaboration agreement with Novartis AG (NYSE: NVS) for its PTC518 Huntington’s disease program, which includ...
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecule...
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.
Olema in deal with Novartis on Kisqali breast cancer combo collaboration
Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%
Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%